ReviewArchives of microbiology2026
Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Candicidal Effect of a Nanoemulsion Based on the Essential Oil of the Medicinal PlantPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections, particularly those caused by dermatophytes, affect over 25% of the world's population and pose a significant public health risk to both humans and animals. Conventional antifungal treatments face substantial challenges like drug resistance, adverse effects, and require long-term systemic medications. Essential oils (EOs) have attracted attention for their antimicrobial properties; however, their therapeutic applications have been hampered by their low solubility and rapid degradation. Nanotechnology addresses these limitations by encapsulating EOs to enhance their durability, bioavailability, and antifungal properties. This review covers the potential EO-based nanoformulations for treating fungal infections, with a focus on dermatophytes. It also highlights how nanoencapsulation may help reduce drug resistance, toxicity, and adverse effects. However, there are some limitations. The effectiveness of treating fungal infection can vary depending on the EO's composition, fungal species, and how the nanoformulation is formulated. Future research should emphasize standardizing formulation protocol and evaluating in vivo efficacy and safety through well-designed clinical trials. While EOs represent a promising approach, they are not a substitute for evidence-based antifungal treatment and must not be used without medical guidance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.